Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.72 USD 1.09% Market Closed
Market Cap: 572.3m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

Intrinsic Value

MREO latest financial reports are more than 2 years old.
MREO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MREO stock under the Base Case scenario is 2.28 USD. Compared to the current market price of 3.72 USD, Mereo Biopharma Group PLC is Overvalued by 39%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MREO Intrinsic Value
2.28 USD
Overvaluation 39%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mereo Biopharma Group PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MREO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MREO?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Mereo Biopharma Group PLC

Provide an overview of the primary business activities
of Mereo Biopharma Group PLC.

What unique competitive advantages
does Mereo Biopharma Group PLC hold over its rivals?

What risks and challenges
does Mereo Biopharma Group PLC face in the near future?

Has there been any significant insider trading activity
in Mereo Biopharma Group PLC recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mereo Biopharma Group PLC.

Provide P/S
for Mereo Biopharma Group PLC.

Provide P/E
for Mereo Biopharma Group PLC.

Provide P/OCF
for Mereo Biopharma Group PLC.

Provide P/FCFE
for Mereo Biopharma Group PLC.

Provide P/B
for Mereo Biopharma Group PLC.

Provide EV/S
for Mereo Biopharma Group PLC.

Provide EV/GP
for Mereo Biopharma Group PLC.

Provide EV/EBITDA
for Mereo Biopharma Group PLC.

Provide EV/EBIT
for Mereo Biopharma Group PLC.

Provide EV/OCF
for Mereo Biopharma Group PLC.

Provide EV/FCFF
for Mereo Biopharma Group PLC.

Provide EV/IC
for Mereo Biopharma Group PLC.

Show me price targets
for Mereo Biopharma Group PLC made by professional analysts.

What are the Revenue projections
for Mereo Biopharma Group PLC?

How accurate were the past Revenue estimates
for Mereo Biopharma Group PLC?

What are the Net Income projections
for Mereo Biopharma Group PLC?

How accurate were the past Net Income estimates
for Mereo Biopharma Group PLC?

What are the EPS projections
for Mereo Biopharma Group PLC?

How accurate were the past EPS estimates
for Mereo Biopharma Group PLC?

What are the EBIT projections
for Mereo Biopharma Group PLC?

How accurate were the past EBIT estimates
for Mereo Biopharma Group PLC?

Compare the revenue forecasts
for Mereo Biopharma Group PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mereo Biopharma Group PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mereo Biopharma Group PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mereo Biopharma Group PLC compared to its peers.

Compare the P/E ratios
of Mereo Biopharma Group PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Mereo Biopharma Group PLC with its peers.

Analyze the financial leverage
of Mereo Biopharma Group PLC compared to its main competitors.

Show all profitability ratios
for Mereo Biopharma Group PLC.

Provide ROE
for Mereo Biopharma Group PLC.

Provide ROA
for Mereo Biopharma Group PLC.

Provide ROIC
for Mereo Biopharma Group PLC.

Provide ROCE
for Mereo Biopharma Group PLC.

Provide Gross Margin
for Mereo Biopharma Group PLC.

Provide Operating Margin
for Mereo Biopharma Group PLC.

Provide Net Margin
for Mereo Biopharma Group PLC.

Provide FCF Margin
for Mereo Biopharma Group PLC.

Show all solvency ratios
for Mereo Biopharma Group PLC.

Provide D/E Ratio
for Mereo Biopharma Group PLC.

Provide D/A Ratio
for Mereo Biopharma Group PLC.

Provide Interest Coverage Ratio
for Mereo Biopharma Group PLC.

Provide Altman Z-Score Ratio
for Mereo Biopharma Group PLC.

Provide Quick Ratio
for Mereo Biopharma Group PLC.

Provide Current Ratio
for Mereo Biopharma Group PLC.

Provide Cash Ratio
for Mereo Biopharma Group PLC.

What is the historical Revenue growth
over the last 5 years for Mereo Biopharma Group PLC?

What is the historical Net Income growth
over the last 5 years for Mereo Biopharma Group PLC?

What is the current Free Cash Flow
of Mereo Biopharma Group PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mereo Biopharma Group PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Mereo Biopharma Group PLC

Current Assets 93.9m
Cash & Short-Term Investments 87.4m
Receivables 2.3m
Other Current Assets 4.3m
Non-Current Assets 2.2m
PP&E 1.3m
Intangibles 866k
Current Liabilities 15.5m
Accounts Payable 2.7m
Accrued Liabilities 4.4m
Other Current Liabilities 8.4m
Non-Current Liabilities 2m
Other Non-Current Liabilities 2m
Efficiency

Earnings Waterfall
Mereo Biopharma Group PLC

Revenue
10m GBP
Cost of Revenue
-2.6m GBP
Gross Profit
7.4m GBP
Operating Expenses
-58.6m GBP
Operating Income
-51.1m GBP
Other Expenses
458k GBP
Net Income
-50.7m GBP

Free Cash Flow Analysis
Mereo Biopharma Group PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MREO Profitability Score
Profitability Due Diligence

Mereo Biopharma Group PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive Gross Profit
ROE is Increasing
Exceptional 1-Year Revenue Growth
28/100
Profitability
Score

Mereo Biopharma Group PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

MREO Solvency Score
Solvency Due Diligence

Mereo Biopharma Group PLC's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Mereo Biopharma Group PLC's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MREO Price Targets Summary
Mereo Biopharma Group PLC

Wall Street analysts forecast MREO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MREO is 7.34 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.

Lowest
Price Target
6.06 USD
63% Upside
Average
Price Target
7.34 USD
97% Upside
Highest
Price Target
8.4 USD
126% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MREO?

Click here to dive deeper.

Dividends

Mereo Biopharma Group PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for MREO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MREO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

573.9m USD

Dividend Yield

0%

Description

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

Contact

London
Fourth Fl, 1 Cavendish Place
+443330237300.0
www.mereobiopharma.com

IPO

2016-06-09

Employees

49

Officers

Co-Founder, CEO & Executive Director
Dr. Denise Vera Scots-Knight Ph.D.
Co-Founder, General Counsel, Business Development & Company Secretary
Mr. Charles Edward Sermon
Chief Financial Officer
Ms. Christine Fox CPA
Co-Founder & Chief Business Officer
Dr. John P. Richard M.B.A.
Chief Scientific Officer
Dr. John A. Lewicki Ph.D.
Senior VP & Therapeutic Head
Dr. Jackie Parkin
Show More
Chief of Patient Access & Commercial Planning
Ms. Alexandra Hughes-Wilson
Senior Vice President of Clinical Development
Dr. Suba Krishnan
Senior VP and Head of Pharmaceutical Development & CMC
Mr. Bo Kara
Show Less

See Also

Discover More
What is the Intrinsic Value of one MREO stock?

The intrinsic value of one MREO stock under the Base Case scenario is 2.28 USD.

Is MREO stock undervalued or overvalued?

Compared to the current market price of 3.72 USD, Mereo Biopharma Group PLC is Overvalued by 39%.

Back to Top